钱锋，清华大学药学院院长、拜耳讲席教授，现任北京市视觉科学与转化医学研究中心（Beijing Visual Science and Translational Eye Research Institute）核心PI、"口服药物智能设计与递送"北京市重点实验室主任。钱锋教授本科及硕士毕业于清华大学材料科学与工程系，后于美国凯斯西储大学（Case Western Reserve University）获生物医学工程博士学位。2012年加入清华大学前，曾任百时美施贵宝公司（Bristol-Myers Squibb）主任科学家，主导新型药物递送技术研究、新药研发管理、外部学术合作及技术评价等工作。钱锋实验室立足对临床需求的深入理解和对疾病生物学机制的探究，融合工程化药物设计理念与先进药物递送技术，致力于解决致盲性眼底疾病、肿瘤等重大疾病的未满足临床需求。团队重点研究药物穿透各类生理屏障的机制、药物在细胞与组织层面的转运规律，以及药物与材料的相互作用，据此设计创新递送技术，以优化药物递送效率与生物分布、提升靶向性与安全性，最终实现最佳治疗效果、安全性及患者依从性。钱锋教授的制剂与新药研究已推动多款药物在中美两地进入临床试验及商业化阶段，发表同行评议论文80余篇。现任Molecular Pharmaceutics副主编，兼任中国药学会药剂学专业委员会与监管科学专业委员会委员。
Prof. Feng Qian is Dean of the School of Pharmaceutical Sciences at Tsinghua University and Bayer Endowed Chair Professor. He also serves as a Principal Investigator at the Beijing Visual Science and Translational Eye Research Institute (BERI) and Director of the Beijing Key Laboratory of Oral Drug Intelligent Design and Delivery. Prof. Qian received his B.S. and M.S. in Materials Science and Engineering from Tsinghua University, and his Ph.D. in Biomedical Engineering from Case Western Reserve University. Prior to joining Tsinghua in 2012, he was a Principal Scientist at Bristol-Myers Squibb, where he led research on novel drug delivery technologies, new drug development management, external academic collaborations, and technology evaluation.
The Qian Laboratory builds upon a deep understanding of clinical needs and the investigation of disease biological mechanisms, combining engineering-based drug design principles with advanced drug delivery technologies to address unmet clinical needs in major diseases such as blinding retinal diseases and cancer. The team focuses on elucidating the mechanisms by which drugs penetrate various physiological barriers, drug transport at the cellular and tissue levels, and drug-material interactions. Building on these insights, the lab designs innovative delivery technologies to optimize drug delivery efficiency and biodistribution, enhance targeting and safety, and ultimately achieve optimal therapeutic outcomes, safety profiles, and patient compliance.
Prof. Qian's research in drug delivery and new drug development has contributed to multiple drug candidates entering clinical trials and commercialization in both China and the United States. He has published over 80 peer-reviewed papers and serves as Associate Editor of Molecular Pharmaceutics. He is also a Committee Member of the Pharmaceutics Professional Committee and the Regulatory Science Professional Committee of the Chinese Pharmaceutical Association.
